Results 1 to 10 of about 207,653 (256)
PB2426: SORAFENIB MAINTENANCE TAILORED TO FLT3-MUTATED AML AFTER ALLOGENEIC HCT IS HIGHLY FEASIBLE AND EFFECTIVE: A REAL-LIFE EXPERIENCE
HemaSphere, 2023 Elisa Diral, Giulia Furnari, Francesca Farina, Daniela Clerici, Sarah Marktel, Raffaella Greco, Gloria Catalano, Alessandro Bruno, Edoardo Campodonico, Elisabetta Xue, Sara Mastaglio, Luca Vago, Massimo Stefano Luca Bernardi, Matteo Giovanni Carrabba, Consuelo Corti, Jacopo Peccatori, Fabio Ciceri, Maria Teresa Lupo Stanghellini +17 moredoaj +1 more sourceTransplantation of viable meniscal allograft : surgical technique [PDF]
, 2006 Almqvist, Karl, Demurie, Alex, Verbruggen, August, Verdonk, Peter, Verdonk, René, Veys, Eric +5 morecore +2 more sources[Bone transplant].
Anales del sistema sanitario de Navarra, 2007 We describe the methodology of the Bone and Soft Tissue Bank, from extraction and storage until use. Since the year 1986, with the creation of the Bone Bank in the University Clinic of Navarra, more than 3,000 grafts have been used for very different types of surgery.M, San Julián, A, Valentíopenaire +1 more sourceTreatment of pediatric acute lymphoblastic leukemia in India on BFM 95 protocol backbone with relevant modifications and minimal residual disease application - Doable and effective
Pediatric Hematology Oncology Journal, 2022 Dhwanee Thakkar, K. Upasana, Sunisha Arora, Ritu Chadha, D.S. Udayakumar, Bhawna Jha, Anjali Yadav, Neha Rastogi, Shalini Goel, Renu Saxena, Satya Prakash Yadav +10 moredoaj +1 more sourceMesenchymal stem cells and their use as cell replacement therapy and disease modelling tool. [PDF]
, 2008 Mesenchymal stem cells (MSCs) from adult somatic tissues may differentiate in vitro and in vivo into multiple mesodermal tissues including bone, cartilage, adipose tissue, tendon, ligament or even muscle. MSCs preferentially home to damaged tissues where García-Castro, J, Madrenas, J, Menendez, P, Pérez-Simón, JA, Rodriguez, R, Trigueros, C +5 morecore FAPα+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD‐L1 and T Cell Senescence
Advanced ScienceMultiple myeloma (MM) is a hematologic malignancy driven by clonal expansion of malignant plasma cells. Despite the long‐term disease control achieved with immunotherapies in some patients, treatment resistance remains a major cause of disease relapse ...Huiyao Gu, Zhenfeng Dai, Xi Huang, Enfan Zhang, Xinyuan Dai, Haoguang Chen, Wen Cao, Jinna Zhang, Yifan Hou, Haimeng Yan, Yang Yang, Li Yang, Yi Li, Wenlong Lin, Zhen Cai, Jingsong He +15 moredoaj +1 more sourceBuilding blocks of hematology in the last 3 decades in Pakistan
Blood Advances, 2019 Tahir S. Shamsi, Tasneem Farzana, Saqib Ansari, Nazli Hossain, Arshi Naz, Munira Borhany, Mehwesh Taj, Saima Munzir, Uzma Zaidi, Jawwad Hassan, Nida Irfan, Nazmeen Shakoor, Farah Mubarak, Kouser Parveen, Syeda Anwari, Nadeem Ahmed, Mansoor Hussain, Irfan Ghafoor Baig, Dilnasheen Safdar, Sadaf Shahab +19 moredoaj +1 more sourcePB1967: EVALUATION OF A TRIAL OF IMATIB* DOSE TAPERING IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE: RESULTS AT 4.5 YEARS
HemaSphere, 2023 Naima Abdennebi, Fateh Boukhemia, Farida Harieche, Nacera Ait Amer, Farida Tensaout, Hanane Moussaoui, Sabrina Akhrouf, Malek Benakli, Rose-Marie Hamladji, Redhouane Ahmed-Nacer +9 moredoaj +1 more source